# NVO — slm-full-gpu

## Metadata

ticker: NVO
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: 096eec5c28fdcb9394d6128522010bf95bbdbc37efcebfe54f4f3e5983a99880
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 5
llm_endpoints: slm-gpu
llm_by_site: {"section:financial_health": {"calls": 1, "completion_tokens": 139, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 6.585, "latency_s_total": 6.585, "parse_failure": 0, "prompt_tokens": 455, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 89, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 7.171, "latency_s_total": 7.171, "parse_failure": 0, "prompt_tokens": 449, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 167, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 10.053, "latency_s_total": 10.053, "parse_failure": 0, "prompt_tokens": 445, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 97, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 9.591, "latency_s_total": 9.591, "parse_failure": 0, "prompt_tokens": 453, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 774, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 11.611, "latency_s_total": 11.611, "parse_failure": 0, "prompt_tokens": 1420, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "NVO",
  "company_name": "Novo Nordisk A/S",
  "current_price": 38.26,
  "currency": "USD",
  "market_cap": 168893218816.0,
  "pe_ratio": 9.354523,
  "forward_pe": 11.501758,
  "week_52_high": 64.16,
  "week_52_low": 35.12,
  "financial_currency": "DKK",
  "revenue": 329430990848.0,
  "net_income": 116442996736.0,
  "profit_margin_pct": 35.35,
  "dividend_yield": 4.79,
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General"
}

NEWS ARTICLES:
[
  {
    "title": "Novo Nordisk Slims Down Name to Novo",
    "source": "The Wall Street Journal",
    "published_at": "2026-09-14T12:41:00Z",
    "description": "The Wegovy maker is betting that a shorter name will help it resonate more with consumers as it competes with rival Eli Lilly."
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "message": "No 10-K found"
  },
  "10-Q": {
    "message": "No 10-Q found"
  }
}

RAG — SEC HIGHLIGHTS:
(not available)

RAG — RISK FACTORS:
(not available)

## Pre-written sections (judge input)

### Financial Health

Novo Nordisk trades at $38.26 with a market capitalization of approximately $168.9 billion, reflecting a compelling valuation with a P/E ratio of 9.35. The company demonstrates exceptional profitability, reporting a profit margin of 35.35% on revenue of DKK 329.4 billion and net income of DKK 116.4 billion. This strong financial foundation is further supported by a dividend yield of 4.79%, indicating robust cash generation capabilities. Despite trading near its 52-week low, the stock's fundamental metrics suggest significant operational efficiency and market strength.

### Recent Developments
Novo Nordisk has officially rebranded to "Novo," a strategic move designed to enhance consumer resonance and strengthen its competitive position against rival Eli Lilly in the weight-loss drug market. This branding shift underscores the company's aggressive expansion beyond its traditional diabetes focus into the broader obesity treatment sector. Investors should monitor how this simplified identity impacts brand equity and market share growth in the highly contested GLP-1 arena.

### SEC Filing Highlights
No recent 10-K or 10-Q filings are currently available for review. Consequently, financial performance is assessed based on reported revenues of DKK 329.4 billion and net income of DKK 116.4 billion. The company maintains a robust profit margin of 35.35%, underscoring strong operational efficiency. Investors should monitor for upcoming SEC submissions to verify these figures against recent quarterly results.

### Risk Factors

*   **Brand Rebranding Execution Risk:** The strategic shift to shorten the corporate name to "Novo" carries execution risk, as the company bets that this change will successfully enhance consumer resonance and competitive positioning against rivals like Eli Lilly.
*   **Regulatory and Patent Landscape:** As a primary manufacturer of GLP-1 agonists (e.g., Wegovy), the company faces ongoing risks related to patent litigation, regulatory approval delays, and potential pricing pressures or reimbursement restrictions in key global markets.
*   **Market Volatility and Valuation:** Despite strong profitability, the stock has experienced significant volatility, trading well below its 52-week high of $64.16, which may reflect investor concerns regarding long-term growth sustainability and competitive intensity in the obesity and diabetes treatment sectors.

## Audited (Exec Summary + Outlook)

### Executive Summary
Novo Nordisk is a dominant force in the diabetes and obesity treatment sectors, leveraging a robust financial foundation characterized by a 35.35% profit margin on DKK 329.4 billion in revenue. The stock is currently notable for its significant discount to recent highs, presenting a compelling valuation profile despite ongoing competitive pressures in the GLP-1 market. The single most important near-term variable is the successful execution of the corporate rebranding to "Novo" and its subsequent impact on consumer resonance and market share against rivals like Eli Lilly.

### Outlook
The directional outlook for Novo Nordisk is cautiously constructive, anchored by exceptional profitability and strong cash generation, yet tempered by intense competitive dynamics in the obesity treatment space. Key variables to monitor include the efficacy of the "Novo" rebranding in driving consumer engagement, the trajectory of GLP-1 market share relative to competitors, and any shifts in regulatory or reimbursement landscapes that could impact pricing power. The thesis would be strengthened by clear evidence that the brand simplification translates into sustained demand growth and market expansion, while it would be weakened by signs of margin compression due to pricing pressures or execution missteps in the rebranding strategy.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "35.35% profit margin"
LABEL: SUPPORTED
REASON: The source data explicitly states `"profit_margin_pct": 35.35`, and the pre-written sections confirm "profit margin of 35.35%."

---

CLAIM: "DKK 329.4 billion in revenue"
LABEL: SUPPORTED
REASON: The source data shows `"revenue": 329430990848.0` in DKK (financial_currency: DKK), which rounds to DKK 329.4 billion, consistent with the pre-written sections.

---

CLAIM: "significant discount to recent highs"
LABEL: SUPPORTED
REASON: The current price of $38.26 is arithmetically well below the 52-week high of $64.16 (a ~40.4% discount), confirming the directional positional claim.

---

**OUTLOOK**

---

CLAIM: "exceptional profitability"
LABEL: SUPPORTED
REASON: A 35.35% profit margin and net income of DKK 116.4 billion on DKK 329.4 billion revenue are present in the source data and support this characterization.

---

CLAIM: "strong cash generation"
LABEL: INFERENCE
REASON: The source data shows a dividend yield of 4.79% and a profit margin of 35.35%, from which strong cash generation is a reasonable directional inference, though no explicit free cash flow figure is provided in the source data.

---

*No additional specific quantitative figures, price targets, thresholds, ratios, named product milestones, or forward-looking numbers appear in the Outlook section beyond those already evaluated above. All remaining language in the Outlook is qualitative and directional (e.g., "cautiously constructive," "intense competitive dynamics," "margin compression"), which falls outside the scope of quantitative claim verification.*

---

**SUMMARY TABLE**

| # | Claim | Label |
|---|-------|-------|
| 1 | 35.35% profit margin | SUPPORTED |
| 2 | DKK 329.4 billion in revenue | SUPPORTED |
| 3 | Significant discount to recent highs | SUPPORTED |
| 4 | Exceptional profitability (Outlook) | SUPPORTED |
| 5 | Strong cash generation (Outlook) | INFERENCE |
